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Genetic polymorphisms have been demonstrated to be associated with vulnerability to human infection.
ICAM3, an intercellular adhesion molecule important for T cell activation, and FCER2 (CD23), an immune
response gene, both located on chromosome 19p13.3, were investigated for host genetic susceptibility and
association with clinical outcome. A case-control study based on 817 patients with confirmed severe acute
respiratory syndrome (SARS), 307 health care worker control subjects, 290 outpatient control subjects, and
309 household control subjects unaffected by SARS from Hong Kong was conducted to test for genetic
association. No significant association to susceptibility to SARS infection caused by the novel coronavirus
(SARS-CoV) was found for the FCER2 and the ICAM3 single nucleotide polymorphisms. However, patients
with SARS homozygous for ICAM3 Gly143 showed significant association with higher lactate dehydrogenase
levels ( ; odds ratio [OR], 4.31 [95% confidence interval {CI}, 1.37–13.56]) and lower total whitePp .0067
blood cell counts ( ; OR, 0.30 [95% CI, 0.10–0.89]) on admission. These findings support the role ofPp .022
ICAM3 in the immunopathogenesis of SARS.
Severe acute respiratory syndrome (SARS) caused by
the novel coronavirus (SARS-CoV) occurred largely in
Chinese communities and in Asian countries [1]. A
proportion of persons exposed to the virus without
adequate protection, however, did not develop the dis-
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ease [2]. It has been reported that of the close contacts
of all 1755 patients with SARS diagnosed and treated
in Hong Kong, only 14% actually died of the disease;
the reason for this has yet to be discovered. Genetic
polymorphisms have been demonstrated to be associ-
ated with vulnerability to a variety of human infections,
including SARS [3]. Association between susceptibility
to SARS and the major histocompatibility complex
(MHC) class I has also been reported (e.g., the HLA-
B*4601 allele [4] and HLA-B*0703 allele from Hong
Kong [5]). However, the subject numbers in both these
studies had been small.
The angiotensin-converting enzyme–2 (ACE2) is the
only known functional receptor for SARS-CoV infec-
tion/replication [6], but no significant association for
susceptibility or clinical outcome has been shown with
the polymorphisms of the ACE2 gene [7]. DC-SIGN
(dendritic cell [DC]–specific intercellular adhesion
molecule-3 [ICAM3]–grabbing nonintegrin, encoded
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Table 1. Demographic features of patients with severe acute respiratory syndrome
(SARS) and control subjects.
Characteristic
Patients with SARS Control subjects
Initially
recruited
(n p 309)
All
(n p 817)
Health
care workers
(n p 307)
Household
contacts
(n p 309)
Outpatients
(n p 260)
Age, years
Mean (SD) 41.2 (14.3) 40.26 (13.8) 34.7 (9.6) 41.8 (14.3) 49.9 (19.8)
Median 40.0 38.0 33.0 43.0 47.0
Range 5–85 5–88 21–60 18–80 4–95
Sex
Male:female 2:3 2:3 2:6.6 2:2.4 2:4
Female, no. (%) 188 (61.1) 505 (61.8) 235 (76.5) 168 (54.4) 173 (66.5)
by CD209) is an important C-type lectin expressed on DCs
that can bind pseudovirus transfected by the SARS spike gene
[8, 9]. L-SIGN (liver/lymph node–specific ICAM3 grabbing
nonintegrin, encoded by CLEC4M) is a homologue of DC-
SIGN and is also a binding receptor for SARS-CoV infection
[10]. Interestingly, DC-SIGN, L-SIGN, and FCER2 ICAM3
genes are all mapped on 19p13.3, within 71 kb of each other,
and belong to the C-type lectin family [11], whereas ICAM3
is the natural ligand for both DC-SIGN and L-SIGN [12, 13].
ICAM3, being expressed constitutively on T cells and other
leukocytes, is a potent signalling molecule and a major ligand
in the initiation of T cell–mediated immune responses [14, 15].
In addition to the recognition of peptide/MHCs on the surface
of professional antigen presenting cells (APCs), such as DC
[16], by the T cell receptors on the T cell surface, the interaction
of adhesion molecules between the APCs and T cells are also
critical for activating antigen-specific T cells [17]. The binding
between ICAM3 and its ligands DC-SIGN or leukocyte func-
tion–associated antigen–1 [18] provides transient engagement
of naive T cells with DCs, which then allows the T cells to
sample large numbers of MHC molecules for the presence of
specific peptides [19]. This initial cell-to-cell engagement step
is critical for induction of T cell responses, which in turn play
a central role in the immunoregulation of infectious diseases.
It is noteworthy that circulating forms of ICAM3 have been
used as a parameter to monitor disease progression, particularly
in HIV-infected patients [20]. However, the role of ICAM3 in
settings of other viral infection, such as SARS-CoV infection,
is still unknown.
As the association between specific MHC alleles and suscep-
tibility to SARS has been observed, we hypothesized that poly-
morphisms of other related molecules such as ICAM3, FCER2,
DC-SIGN, and L-SIGN may influence susceptibility to SARS-
CoV infection. We have previously shown that individuals ho-
mozygous for the tandem neck repeats of L-SIGN (CLEC4M)
gene are less susceptible to SARS infection [21]. In the present
case-control genetic association study, we report that the Gly143
polymorphism of ICAM3 are associated with higher lactate
dehydrogenase (LDH) levels and lower total white blood cell
(WBC) counts on admission in patients with SARS-CoV
infection.
PATIENTS, MATERIALS, AND METHODS
Subjects were recruited for this study after approval from the
respective institutional review boards of hospitals involved. In-
formed signed consent was obtained from subjects donating 6
mL of peripheral blood.
Patients with SARS. The initial study included 309 patients
with confirmed SARS recruited from 3 major hospitals that
treated patients with SARS in Hong Kong during the 2003
outbreak, namely, Pamela Youde Nethersole Hospital, Princess
Margaret Hospital, and United Christian Hospital. Subse-
quently, we further recruited 508 patients with SARS from SARS
follow-up outpatient clinics in the 3 previously mentioned hos-
pitals and 3 others, namely, Queen Mary Hospital, Alice Ho
Miu Ling Nethersole Hospital, and Prince of Wales Hospital.
All 817 patients with SARS were confirmed by serologic analysis
and/or reverse-transcriptase polymerase chain reaction (PCR).
Their clinical data were retrospectively obtained from Hospital
Authority, Hong Kong, with permission from all attending cli-
nicians of the respective hospitals. These included age; sex;
length of hospital stay; treatment in an intensive care unit (ICU)
and duration of ICU treatment; whether patients required as-
sisted ventilation, steroid treatment, pulse steroids, or intra-
venous immunoglobulin (IVIG); and final outcome in terms
of survival and death. Because most of the patients were re-
cruited from the SARS follow-up clinics after discharge, the
proportion of deaths was small and could not be used as a
measure of outcome. Results of hematological and biochemical
laboratory investigations on admission were also retrieved.
These included hemoglobin level, absolute lymphocyte count,
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Table 2. Clinical profile of patients with severe acute respira-
tory syndrome (SARS) recruited for study.
Characteristic
Initially
recruited All
Treated in ICU 59 (21.7) 136 (16.6)
Required ventilation 46 (16.9) 76 (9.3)
Received steroid treatment 258 (94.9) 795 (97.3)
Received pulse steroid/IVIG 163 (60.0) 517 (63.3)
Length of hospital stay, days
Mean (SD) 33.2 (16.9) 28.23 (17.9)
Median (range) 28.0 (4–169) 23.0 (4–235)
Death 12 (4.4) 12 (1.5)
Length of ICU stay, days
Mean (SD) 9.0 (17.1) 2.66 (10.8)
Median (range) 9.0 (1–80) 0 (0–139)
NOTE. Data are no. (%), unless otherwise indicated. ICU, intensive care
unit; IVIG, intravenous immunoglobulin.
Table 3. Relationship of household contacts with patients with
severe acute respiratory syndrome.
Relationship
Contacts,
no. (%)
Father, mother, son, daughter, brother, and sister 178 (57.7)
Grandfather, grandmother, aunt, uncle, nephew,
niece, and cousin 10 (3.2)
Family member without blood relationship (e.g.,
husband, wife, son/daughter-in-law, brother/
sister-in-law, stepfather, etc.) 102 (33.0)
Contacts with no family relationship (e.g., friend,
domestic helper, etc.) 19 (6.1)
Total 309
platelet count, WBC count, and biochemical indices of alanine
aminotranseferase, albumin, globulin, creatinine kinase, LDH,
urea, sodium, potassium, and serum creatinine.
Controls. Three control groups were recruited for this
study. For our initial analysis, we recruited unaffected health
care workers (HCWs) who had worked in SARS wards, who
had worked in SARS ICU or cohort wards for patients with
suspected SARS, and/or who had performed high-risk proce-
dures. All 307 who had volunteered for the study remained
disease free and were confirmed to be seronegative for SARS
at the end of the outbreak. A simple self-administered ques-
tionnaire documented the type of wards they had worked in,
the duration of work, and whether they had performed high-
risk procedures such as ambu-bagging, nasopharyngeal suction,
tracheal intubation, endotracheal suction, disposal of excreta,
chest physiotherapy, and feeding of highly dependent patients.
Subsequently, 2 further groups of controls were also recruited:
outpatient control (OPC) subjects consisting of 290 individuals
randomly recruited from the general outpatient clinics at least
2 months after the SARS outbreak with no clinical history or
signs or symptoms of inflammation or infection and household
contact control (HHC) subjects consisting of 309 household
members of patients with SARS who remained unaffected and
confirmed to be seronegative at the end of the outbreak. All
HHC subjects recruited were asked to state their relationship
with the patient(s) with SARS as well as with other family
members in the household. To prevent genotype and allele
frequency distribution bias, family members of the same house-
hold who were genetically related were taken into consideration
in the statistical analysis of genotypes. All control subjects were
Chinese from Hong Kong.
Genomic DNA from peripheral blood samples were extracted
following conventional methods, adopting level 3 biosafety pre-
cautions in accordance with the World Health Organization
and Centers for Disease Control and Prevention guidelines. The
HHC subjects donated saliva samples for extraction of buccal
DNA by Oragene DNA Self-Collection Kit (DNA Genotek).
Selection of polymorphisms for study. Nonsynonymous
coding single nucleotide polymorphisms (nsSNPs) and 3′ un-
translated region (3′UTR) SNPs of ICAM3, FCER2, DC-SIGN,
and L-SIGN were identified from the National Center for Bio-
technology Information dbSNP database (http://www.ncbi
.nlm.nih.gov/projects/SNP/). We specifically looked for nsSNPs
that may result in structural changes of the encoded protein
leading to functional effect, as well as 3′UTR SNPs. At the time
the study was initiated, no nsSNPs or 3′UTR SNPs were re-
ported for DC-SIGN. Allele frequency of the SNPs was first
evaluated in 90 unaffected healthy individuals, and only those
with minor allele frequency 15% were further investigated. Five
SNPs for FCER2 and 1 for ICAM3 were thus selected for study.
The nsSNP for L-SIGN with minor allele frequency !5% was
not further investigated.
Genotyping by Sequenom. Genotyping of the initial SARS
samples (309 cases) and HCW control subjects was done by
Sequenom. MassARRAY AssayDesign software (Sequenom) was
used to design amplification and allele-specific extension. PCRs
were performed in 384-well plate format, and the amplified
products were treated with alkaline phosphatase. The final al-
lele-specific base extension was performed and then treated
with SpectroClean (Sequenom) resin. Extended products were
dispensed onto SpectroCHIP (Sequenom), separated by Bruck-
er Autoflex MALDI-TOF mass spectrometer (Brucker) and an-
alyzed by SpectroTYPER (Sequenom). In every plate assayed,
there was 1 well for blank control and 5 wells for duplicate
check on 5 samples for quality control.
Genotyping of the additional SARS samples and HHC and
OPC group samples for the ICAM3 Gly143 SNP was performed
by Allelic Discrimination TaqMan Assay (assay C_15974025_10;
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Table 4. Genotype and allele frequencies of ICAM3 and FCER2 polymorphisms.
Polymorphism Genotype
Initially recruited
patients with SARS HCW control subjects
OR (95% CI) PNo. % HWE P No. % HWE P
ICAM3
rs2304237 (Asp143Gly) TT/CT/CC
(Asp/GlyAsp/Gly)
194/49/2 79.2/20/0.8 .566 265/26/6 89.2/8.8/2.0 3.55  106 2.17 (1.35–3.52)a .001
FCER2
rs4804773 (Trp62Arg) CC/TC/TT
(Trp/ArgTrp/Arg)
213/34/2 85.5/13.7/0.8 .621 246/36/4 86.0/12.6/1.4 .055 … .855
rs889182 TT/TC/CC 186/56/6 75.0/22.6/2.4 .472 154/55/3 72.6/25.9/1.4 .439 … .092
rs1990975 GG/GA/AA 175/61/7 72.0/25.1/2.9 .551 151/55/3 72.2/26.3/1.4 .421 … .103
rs2287868 GG/GA/AA 106/104/28 44.5/43.7/11.8 .747 89/103/16 42.8/49.5/7.7 .062 … .732
rs2303112 AA/CA/CC 92/115/40 37.2/46.6/16.2 .687 62/117/32 29.4/55.5/15.2 .055 … .064
Allele
ICAM3
rs2304237 (Asp143Gly) T/C (Asp/Gly) 437/53 89.2/10.8 … 556/38 93.6/6.4 … 1.775 (1.148–2.742) .009
FCER2
rs4804773 (Trp62Arg) C/T (Trp/Arg) 460/38 92.4/7.6 … 528/44 92.3/7.7 … … .970
rs889182 T/C 428/68 86.3/13.7 … 363/61 85.6/14.4 … … .768
rs1990975 G/A 411/75 84.6/15.4 … 357/61 85.4/14.6 … … .725
rs2287868 G/A 316/160 66.4/33.6 … 281/135 67.5/32.5 … … .713
rs2303112 A/C 299/195 60.5/39.5 … 241/181 57.1/42.9 … … .295
NOTE. The total no. of cases successfully genotyped for each single nucleotide polymorphism varied, depending on the success call rate generated from
the MassARRAY Analyzer (Sequenom). Bold type indicates statistically significant values. CI, confidence interval; HCW, health care worker; HWE, Hardy-Weinberg
equilibrium; OR, odds ratio; SARS, severe acute respiratory syndrome.
a OR was obtained by comparing combined Gly-allele carriers with homozygous Asp carriers.
Applied Biosystems). The assay was performed according to
conditions as described elsewhere [22]. Each 96-well plate re-
action contained 1 negative control, controls for each genotype
that was examined by direct sequencing, and there were 8 rep-
licated samples.
Risk association analysis. Genotype distributions of the
patient group and the control groups were assessed using the
x2 test using SPSS for Windows (version 13.0), and odds ratio
(OR) and 95% confidence intervals (CIs) were used to measure
strength of association. Hardy-Weinberg equilibrium (HWE)
and pair-wise linkage disequilibrium (LD) analysis were cal-
culated using the x2 test, taking for the level of signif-P ! .05
icance. Haplotype frequencies were estimated using Arlequin
(version 2.00; Genetics and Biometry Laboratory, University of
Geneva) based on expectation-maximization algorithm. The
standardized LD parameter (D′) was evaluated by 2LD [23].
Because a significant proportion of the HHC subjects recruited
were genetically related to each other, we also used logistic
regression with the cluster and robust methods (STATA pro-
gram; version 9; StataCorp) [24] to factor in genetic relations
of all subjects.
Analysis for association with clinical outcome. The x2 test
was used to test for possible association with nominal clinical
outcome measures such as those requiring ICU care and/or
ventilation, requiring pulse steroid and/or IVIG treatment. For
the analysis of numerical variables such as length of hospital
stay and length of ICU stay, and hematological and biochemical
laboratory indices, each of these parameters was first analyzed
by Student’s t test to compare the mean values of patients
having wild-type versus the variant genotype. Because of the
variations in the reference ranges of biochemical indices used
by different hospitals, some of the values, such as LDH, alanine
aminotransferase, and creatinine kinase, were standardized by
dividing the actual values by the upper limit of normal reference
range. Parameters for which significant difference was obtained
were further studied using the x2 test. To identify the appro-
priate cutoff value to partition the values into 2 groups, values
were arranged in ascending order forming a curve that fits a
polynomial trend line. The cutoff value was taken at the in-
flection of the curve or at the point when the values begin to
change exponentially.
RESULTS
Demographic data. The demographic features of the patients
with SARS and the various control groups are summarized in
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Figure 1. Preliminary studies. A, Genotype and allele frequencies of ICAM3 of patients with severe acute respiratory syndrome (SARS) with
normalized lactate dehydrogenase (LDH) levels on admission (as ratio to upper limit of normal reference range). B, Genotype and allele frequencies
of ICAM3 of patients with SARS with white blood cell (WBC) count on admission.
table 1. The clinical features are as summarized in table 2. In
HCW control subjects, there were 269 (87.6%) who had worked
in a SARS ward/SARS ICU, and the remaining 38 (12.4%)
worked either in a suspected SARS cohort ward or in a general
ward that had cared for patients with SARS. They had worked
in these environments for 4–120 days (median, 50 [average,
52] days) during the SARS outbreak, and 178 (58%) had per-
formed high-risk procedures. The 290 OPC subjects had pre-
viously been used in our genetic association study of L-SIGN
for susceptibility to SARS [21]. However, only 260 cases had
sufficient DNA left over for further analysis. The third control
group of 309 HHC subjects was recontacted from the study of
Leung et al. [2]. These consisted of asymptomatic close contact
of patients with SARS who were serologically negative for SARS.
Their relationship to the patients with SARS recruited is as
summarized in table 3.
Genotype analysis of initial sample of 309 patients with
SARS and 307 HCW controls. The genotype and allele fre-
quencies of each of the polymorphisms studied on the initial
cohort of 309 patients with SARS and 307 HCW controls are
summarized in table 4. Genotypes were found to be in HWE
for both the SARS and control populations for all FCER2
and ICAM3 SNPs, except for the ICAM3 Asp143Gly SNP
(rs2304237) in the HCW population. This SNP was included
in our statistical analysis for genetic association because it might
be representing a preselected group with overrepresentation of
protective genotype, accounting for Hardy-Weinberg disequi-
librium. Genotype frequency analysis showed that the ICAM3
Asp143Gly SNPs were found to have significant risk association
for susceptibility to SARS ( , x2 test; OR, 2.17 [95%Pp .001
CI, 1.35–3.52]), with Gly-allele carriers being more at risk for
SARS. Allelic association was also noted ( , x2 test; OR,Pp .009
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Table 5. ICAM3 genotype and allele analyses, with lactate de-
hydrogenase (LDH) levels on admission of patients with severe
acute respiratory syndrome (preliminary).
ICAM3
Lower
LDH
levela
Higher
LDH
levelb OR (95% CI) Pc
Genotyped
TT (Asp) 121 (81.7) 39 (68.4) Reference .013
CT (Gly/Asp) 26 (17.6) 14 (24.6) … .173
CC (Gly) 1 (0.7) 4 (7.0) 12.41 (1.35–114.40) .017
C-carrier
(Gly-carrier)
(CT and CC) 27 (18.3) 18 (31.6) 2.07 (1.03–4.15) .039
Allelee
T (Asp) 268 (90.5) 92 (80.7) Reference …
C (Gly) 28 (9.5) 22 (19.3) 2.29 (1.25–4.20) .006
NOTE. Data are no. (%), unless otherwise indicated. Bold type indicates
statistically significant values. CI, confidence interval; OR, odds ratio.
a Normalized LDH levels on admission were less than the cutoff value (1.2).
b Normalized LDH level on admission were higher than the cutoff value
(1.2).
c
x2 test ( table) for overall genotype.32
d Lower LDH, ; higher LDH, .np 148 np 57
e Lower LDH, ; higher LDH, .np 296 np 114
Table 6. ICAM3 genotype and allele analyses, with white blood
cell (WBC) counts on admission of patients with severe acute
respiratory syndrome (preliminary).
ICAM3
Lower
WBC
counta
Higher
WBC
countb OR (95% CI) Pc
Genotyped
TT (Asp) 45 (68.2) 154 (80.6) Reference .007
CT (Gly Asp) 17 (25.8) 36 (18.9) … .155
CC (Gly) 4 (6.0) 1 (0.5) 0.073 (0.008–0.670) .012
C-carrier
(Gly-carrier) 21 (31.8) 37 (19.4) 0.515 (0.274–0.967) .037
Allelee
T (Asp) 107 (81.1) 344 (90.1) Reference …
C (Gly) 25 (18.9) 38 (9.9) 0.473 (0.273–0.819) .007
NOTE. Data are no. (%), unless otherwise indicated. Bold type indicates
statistically significant values. CI, confidence interval; OR, odds ratio.
a WBC count on admission less than the cutoff value (4.5).
b WBC count on admission higher than the cutoff value (4.5).
c
x2 test ( table) for overall genotype.32
d Lower WBC count, ; higher WBC count, .np 66 np 191
e Lower WBC count, ; higher WBC count, .np 132 np 382
1.775 [95% CI, 1.148–2.742]). None of the 5 FCER2 SNPs
studied showed significant association by genotype or allele
frequency (table 4). The 4 3′UTR FCER2 SNPs were found to
be in LD with each other. On the other hand, ICAM3 was not
in LD with the FCER2 SNPs. Haplotype analysis for FCER2
showed no significant association in the haplotypes ( , x2P 1 .05
test) (data not shown).
There was no significant association found for nominal clin-
ical outcome measures such as those requiring ICU care and/
or ventilation, requiring pulse steroid and/or IVIG treatment
for all the FCER2 and ICAM3 SNPs studied. Other numeric
clinical parameters showed no significant association for the
4 FCER2 SNPs ( , Student’s t test). For the ICAM3P 1 .05
Asp143Gly SNP, however, borderline association for LDH level
was observed ( , comparing homozygous wild-type AspPp .046
versus Gly-allele carriers). An overall significant association
( , x2 test) was observed; homozygous Gly versus ho-Pp .013
mozygous Asp gave (figure 1A and table 5). For WBCPp .017
count, Student’s t test gave for homozygous Gly ver-Pp .005
sus homozygous Asp. An overall significant association was
found ( , x2 test); homozygous Gly versus homozygousPp .007
Asp gave (x2 test). However, the number of cases withPp .012
the homozygous Gly was too small for this significance to be
valid (figure 1B and table 6). Moreover, all these values become
nonsignificant after multiple testing correction for the number
of laboratory indices analyzed ( ) (adjusted ).np 13 Pp .0039
Genotype analysis of additional 508 SARS samples and ad-
ditional control groups for the ICAM3 Asp143Gly SNP. As
the risk association of ICAM3 Asp143Gly SNP was based on
genotyping data for which the control group deviated from
HWE, we further tested for this association using other control
groups. Although the OPC subjects may not necessarily have
been exposed to SARS-CoV, the HHC subjects would have had
similar chance of exposure to SARS-CoV as the HCW control
subjects. Genotype data of both OPC and HHC groups were
in HWE. However, no significant difference in genotype or
allele frequency distribution was found between the initial 309
SARS samples with neither the HHC group nor the OPC group
(data not shown). No significant difference was also found
comparing these 2 control groups with the final SARS sample
size of 817 cases (table 7). From this further analysis, it should
be concluded there is no association of the ICAM3 Asp143Gly
SNP with susceptibility to SARS infection.
The genotype data of the ICAM3 Asp143Gly SNP for the 817
SARS cases was further analyzed for possible association with
LDH levels and WBC counts previously suggested in the initial
SARS samples. Student’s t test showed similar findings as that
of the initial samples. The cutoff values for LDH levels for x2
test were 1.6, dividing the patient into low LDH and high LDH
level groups, whereas that of WBC count was 4.5 (figure 2A
and 2B and tables 8 and 9). For LDH level, the x2 test for
overall genotype gave and homozygous Gly versusPp .015
homozygous Asp gave (OR, 4.31 [95% CI, 1.37–Pp .0067
13.56]). Allelic association was also observed ( ; OR,Pp .0093
1.75 [95% CI, 1.14–2.67]). All P values remained significant
after multiple testing correction ( ) (adjusted ),np 2 Pp .025
thus confirming the association for LDH level on this large
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Table 7. Genotype and allele analysis of the ICAM3 Asp143Gly, of all patients with severe
acute respiratory syndrome (SARS) vs. outpatient control (OPC) subjects and vs. household
contact control (HHC) subjects.
A. ICAM3 genotype and allele frequencies.
ICAM3
Patients with SARS OPC subjects
SARS vs. OPC P aNo. (%) HWE P No. (%) HWE P
Genotypeb .378 .937
TT (Asp) 534 (78.1) 206 (79.2) .783
CT (GlyAsp) 138 (20.2) 51 (19.6) .815
CC (Gly) 12 (1.8) 3 (1.2) .771
C-carrier
(Gly-carrier) 171 (20.9) 54 (20.8) .699
Allelec
T (Asp) 1206 (88.2) 463 (89.0) Reference
C (Gly) 162 (11.8) 57 (11.0) .594
HHC subjects SARS vs. HHC P a
Genotyped .191 .809
TT (Asp) 394 (77.4) 189 (80.1) .581
CT (GlyAsp) 104 (20.4) 44 (18.6) .531
CC (Gly) 11 (2.2) 3 (1.3) .565
C-carrier
(Gly-carrier) 115 (22.6) 47 (19.9) .410
Allelee
T (Asp) 892 (87.6) 422 (89.4) Reference
C (Gly) 126 (12.4) 50 (10.6) .321
B. ICAM3 genotype analysis, taking into account the blood relationships.
SARS vs. HHC OR (95% CI) P
Overall genotypes TT/CT/CC comparison
(Asp/GlyAsp/Gly) 1.10 (0.81–1.49) .545
Non–C-carriers vs. C-carriers
(non–Gly-carriers vs. Gly-carriers) 1.12 (0.80–1.56) .526
NOTE. In part A, patients who were blood related were excluded from analysis; genotype x2 test was
performed using TT (Asp) genotype or T (Asp) allele as reference. In part B, logistic regression model and robust
cluster method were performed using STATA program (version 9). CI, confidence interval; OR, odds ratio.
a
x2 test ( table) for overall genotype.32
b Patients with SARS, ; OPC subjects, .np 684 np 260
c Patients with SARS, ; OPC subjects, .np 1368 np 520
d Patients with SARS, ; HHC subjects, .np 509 np 236
e Patients with SARS, ; HHC subjects, .np 1018 np 472
sample size. Association for WBC count was also demonstrated
for homozygous Gly versus homozygous Asp ( ; OR,Pp .022
0.30 [95% CI, 0.10–0.89]), which remained significant after
multiple testing correction (adjusted ). It is importantPp .025
to note that the homozygous Gly genotype associated with
higher LDH levels was associated on the other hand with lower
WBC counts.
DISCUSSION
In this large genetic association study of SARS susceptibility,
we compared the genotype of 817 patients with SARS with that
of 3 groups of control subjects of 906 unaffected individuals.
Although comparison of patients with SARS genotype with that
of HCW control subjects suggested risk association for the
ICAM3 Asp143Gly SNP, this association could not be confirmed
on comparison with the other 2 control groups. The deviation
from HWE in the HCW control group is intriguing as it was
also observed for the L-SIGN (CLEC4M) tandem-neck repeats
we had previously reported [21], for which genotype had been
confirmed by Southern blot analysis. In that study, the asso-
ciation observed between SARS and HCW control subjects was
confirmed by comparing patients with SARS with outpatient
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Figure 2. A, Genotype and allele frequencies of ICAM3 of all patients with severe acute respiratory syndrome (SARS) with normalized lactate
dehydrogenase (LDH) level on admission (as ratio to upper limit of normal reference range). B, Genotype and allele frequencies of ICAM3 of all
patients with SARS with white blood cell (WBC) counts on admission.
control and random control subjects, which both showed the
same significant association. Because 22% of all patients with
SARS in Hong Kong were HCWs [25], we therefore reckon
that the unaffected health care workers recruited for study may
likely represent a preselected group with overrepresentation of
the protective L-SIGN genotype.
Repeated genotyping of 170 cases from the HCW control
samples using Allelic Discrimination TaqMan Assay recon-
firmed their ICAM3 genotype, which still deviated from HWE
( ). Furthermore, x2 test analysis comparing the4Pp 8.34 10
ICAM3 genotypes of the 817 patients with SARS with these
170 HCW control subjects continued to demonstrate significant
difference ( ). In contrast, the genotype and allele fre-Pp .003
quency distribution of the OPC and HHC groups was very
similar to that of the patients with SARS. It is worth noting
that the age and sex distribution of both OPC and HHC groups
(table 1) is better matched to that of the patients with SARS
recruited than to that of the HCW control subjects. However,
confounding factors such as age and sex had already been ac-
counted for with the use of logistic regression analysis with
adjustment for age and sex (data not shown). The presence of
other confounding factors as yet unaccounted for in this HCW
population probably gave rise to this apparent association.
Thus, with the analysis of 3 control groups, no association of
the ICAM3 Asp143Gly SNP with susceptibility to SARS infec-
tion can be concluded. On the other hand, genotype analysis
of our 817 patients with SARS confirmed the association of
higher LDH levels and lower WBC counts with the homozygous
Gly143 genotype of ICAM3, which supports the role of ICAM3
in the immunopathogenesis of SARS.
The polymorphism ICAM3 Asp143Gly involves the replace-
ment of a large acidic amino acid aspartic acid by a small neutral
amino-acid glycine in the extracellular domain. Although the
protein structure of ICAM3 is not yet disclosed, it is postulated
to be similar to that of ICAM1 [26], whose structure has been
demonstrated [27]. The ICAM3 Asp143Gly SNP is located at
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Table 8. Genotype and allele analysis of the ICAM3 Asp143Gly,
with lactate dehydrogenase (LDH) levels on admission of all pa-
tients with severe acute respiratory syndrome.
ICAM3
Lower
LDH
levela
Higher
LDH
levelb OR (95% CI) Pc
Genotyped
TT (Asp) 469 (80.6) 68 (71.6) Reference .015
CT (GlyAsp) 105 (18) 22 (23.2) … .168
CC (Gly) 8 (1.4) 5 (5.2) 4.31 (1.37–13.56) .007
C-carrier
(Gly-carrier)
(CT and CC) 113 (19.4) 27 (28.4) 1.65 (1.009–2.69) .044
Allelee
T (Asp) 1043 (89.6) 158 (83.2) Reference …
C (Gly) 121 (10.4) 32 (16.8) 1.75 (1.14–2.67) .009
NOTE. Data are no. (%), unless otherwise indicated. Bold type indicates
statistically significant values. CI, confidence interval; OR, odds ratio.
a Normalized LDH levels on admission were less than the cutoff value (1.6).
b Normalized LDH levels on admission were less than the cutoff value (1.6).
c
x2 test ( table) for overall genotype.32
d Lower LDH, ; higher LDH, .np 582 np 95
e Lower LDH, ; higher LDH, .np 1164 np 190
Table 9. Genotype and allele analysis of the ICAM3 Asp143Gly,
with white blood cell (WBC) counts of all patients with severe
acute respiratory syndrome.
ICAM3
Lower
WBC
counta
Higher
WBC
countb OR (95% CI) Pc
Genotyped
TT (Asp) 186 (75.6) 459 (80.7) Reference .047
CT (GlyAsp) 52 (21.1) 104 (18.3) … .270
CC (Gly) 8 (3.3) 6 (1.0) 0.30 (0.10–0.89) .022
C-carrier
(Gly-carrier)
(CT and CC) 60 (24.4) 110 (19.3) … .102
Allelee
T (Asp) 424 (86.2) 1022 (89.8) Reference …
C (Gly) 68 (13.8) 116 (10.2) 0.71 (0.51–0.98) .034
NOTE. Data are no. (%), unless otherwise indicated. Bold type indicates
statistical significant values. CI, confidence interval; OR, odds ratio.
a WBC count on admission less than the cutoff value (4.5).
b WBC count on admission higher than the cutoff value (4.5).
c
x2 test ( table) for overall genotype.32
d Lower WBC, ; higher WBC, .np 246 np 569
e Lower WBC, ; higher WBC, .np 492 np 1138
the junction of domain 1 and 2 and the interchange of an
acidic aspartic acid to a small neutral glycine at this junction
is likely to affect the structuring of ICAM3 and subsequent
dimer formation. Because DC-SIGN/ICAM3 receptor-ligand
pair is crucial for antigen-presenting cells—for example, for
DCs to form immunological synapse with naive T cells—the
association of the ICAM3 Asp143Gly SNP with LDH levels and
WBC counts found in our study suggest that the SNP may
affect the interaction of T cells with DCs, thereby modulating
T cell response in the immunopathogenesis of SARS. We there-
fore postulate that this conformational change may affect the
binding capacity of the receptor, thus affecting lymphocyte ac-
tivation and the initiation of immune response. Further ex-
periments are required to examine this possibility.
The results of this study suggest that, although FCER2 and
ICAM3 SNPs are not associated with susceptibility to SARS-
CoV infection, the ICAM3 Asp143Gly SNP is associated with
LDH levels and lower WBC counts in patients with SARS on
admission. These findings are in keeping with the role of
ICAM3 in T cell activation and the immune response. Asso-
ciation with susceptibility to SARS infection, on the other hand,
would more likely to be found with binding receptors of the
virus, such as L-SIGN, as reported by our group [21]. The
absence of significant association of ICAM3 Asp143Gly with
other clinical parameters is likely related to the fact that the
patients with SARS recruited for our study came from 6 dif-
ferent hospitals throughout Hong Kong. This may have intro-
duced confounding factors that are difficult to eliminate, such
as possible differences in management preferences relating to
the length of hospital stay, ICU care, and decision to initiate
assisted ventilation and administration of steroids. On the other
hand, laboratory parameters were easier to standardize. Other
parameters reported to correlate with clinical outcome such as
viral load and chest x-ray appearances were only available for
a relatively small number of patients.
Although it is generally understood that LDH levels are non-
specific reflections of tissue destruction, the finding of asso-
ciated higher LDH levels with lower WBC counts suggests that
raised LDH levels in patients with SARS may also be the result
of leukocyte destruction associated with immune response. The
finding of decreased peripheral T, B, and NK cells and high
levels of plasma proinflammatory cytokines in patients with
SARS lend support to this [28, 29]. An increase in LDH levels
in the acute phase of SARS infection has been postulated to
be possibly related to immune hyperactivity [30]. High peak
LDH levels have been reported to be an independent predictor
of adverse outcome [31–34]. Thus patients with SARS who are
homozygous for CC genotype of the ICAM3 Asp143Gly SNP
are associated with a 4-fold chance of higher LDH levels on
admission and poorer prognosis. Although the SARS outbreak
appears to have been contained, the molecular determinants
and pathogenesis of SARS remain unclear. Functional studies
to investigate the role of ICAM3 Asp143Gly polymorphism in
influencing the initiation of immune response to SARS-CoV
infection will contribute toward a better understanding of the
pathogenesis of SARS.
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